JP2020502103A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502103A5 JP2020502103A5 JP2019531417A JP2019531417A JP2020502103A5 JP 2020502103 A5 JP2020502103 A5 JP 2020502103A5 JP 2019531417 A JP2019531417 A JP 2019531417A JP 2019531417 A JP2019531417 A JP 2019531417A JP 2020502103 A5 JP2020502103 A5 JP 2020502103A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrimidine
- triazine
- pyrrolo
- trifluoromethyl
- carbonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CN(C)C(C=*1)=C*1N Chemical compound CN(C)C(C=*1)=C*1N 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662435253P | 2016-12-16 | 2016-12-16 | |
| US62/435,253 | 2016-12-16 | ||
| PCT/US2017/066317 WO2018112149A1 (en) | 2016-12-16 | 2017-12-14 | Bycyclic heteroaryl derivatives as cftr potentiators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502103A JP2020502103A (ja) | 2020-01-23 |
| JP2020502103A5 true JP2020502103A5 (enExample) | 2022-05-24 |
| JP7150721B2 JP7150721B2 (ja) | 2022-10-11 |
Family
ID=62557188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531417A Active JP7150721B2 (ja) | 2016-12-16 | 2017-12-14 | Ｃｆｔｒ増強物質としての二環式ヘテロアリール誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10131670B2 (enExample) |
| EP (1) | EP3554506B1 (enExample) |
| JP (1) | JP7150721B2 (enExample) |
| CN (1) | CN110300589B (enExample) |
| AU (2) | AU2017378324B2 (enExample) |
| CA (1) | CA3046968A1 (enExample) |
| MX (1) | MX391651B (enExample) |
| RU (1) | RU2753056C2 (enExample) |
| SG (2) | SG10201911076QA (enExample) |
| WO (1) | WO2018112149A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202140422A (zh) | 2014-10-06 | 2021-11-01 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| US20170166582A1 (en) | 2015-11-25 | 2017-06-15 | Gilead Apollo, Llc | Pyrazole acc inhibitors and uses thereof |
| CN108347939B (zh) | 2015-11-25 | 2021-09-28 | 吉利德阿波罗公司 | 含有2,4-二氧代-1,4-二氢噻吩并[2,3-d]嘧啶的衍生物的杀真菌组合物 |
| EP3380478B1 (en) | 2015-11-25 | 2020-12-23 | Gilead Apollo, LLC | Ester acc inhibitors and uses thereof |
| PL3380479T3 (pl) | 2015-11-25 | 2023-05-08 | Gilead Apollo, Llc | Triazolowe inhibitory acc i ich zastosowania |
| GEP20217329B (en) | 2016-09-30 | 2021-12-10 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| SG10202106949XA (en) | 2016-11-18 | 2021-07-29 | Cystic Fibrosis Found | Pyrrolopyrimidines as cftr potentiators |
| EA202192783A1 (ru) | 2016-12-09 | 2022-02-24 | Вертекс Фармасьютикалз Инкорпорейтед | Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора |
| MA54105A (fr) | 2017-06-08 | 2021-09-15 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| IL272032B2 (en) | 2017-07-17 | 2026-04-01 | Vertex Pharma | Combination therapy for the treatment of cystic fibrosis including N-(1,3-DIMETHYLPYRAZOL-4-YL)SULFONYL-6-[3-(3,3,3-TRIFLUORO-2,2- DIMETHYL-PROPOXY)PYRAZOL-1-YL]-2-[(4S)-2,2,4- TRIMETHYLPYRROLIDIN-1-YL]PYRIDINE-3-CARBOXAMIDE and |
| MA49752A (fr) | 2017-08-02 | 2021-04-21 | Vertex Pharma | Procédés de préparation de composés de pyrrolidine |
| CA3078893A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
| KR102716244B1 (ko) | 2017-12-08 | 2024-10-14 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| RS64018B1 (sr) | 2018-02-15 | 2023-03-31 | Vertex Pharma | Makrocikli kao modulatori transmembranskog regulatora provodnosti cistične fibroze, njihove farmaceutske kompozicije, njihova upotreba u lečenju cistične fibroze i proces njihove izrade |
| WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| TWI848092B (zh) * | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| US20200383960A1 (en) * | 2019-06-10 | 2020-12-10 | Novartis Ag | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis |
| WO2021009695A1 (en) | 2019-07-15 | 2021-01-21 | Novartis Ag | Formulations of (s)-3-amino-6-methoxy-n-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| US11873300B2 (en) | 2019-08-14 | 2024-01-16 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| MX2022012558A (es) * | 2020-04-07 | 2023-02-22 | iTeos Belgium SA | Derivados de diaminas macrocíclicas como inhibidores de ent para el tratamiento de cánceres y combinación de estos con antagonistas del receptor de adenosina. |
| WO2022036060A1 (en) | 2020-08-13 | 2022-02-17 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| CN122537531A (zh) | 2020-08-20 | 2026-08-11 | 小利兰·斯坦福大学托管委员会 | 用于治疗以黏液分泌过多为特征的呼吸系统疾病的方法 |
| US12612416B2 (en) | 2020-10-07 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| MX2023006770A (es) | 2020-12-10 | 2023-08-14 | Vertex Pharma | Metodos de tratamiento para fibrosis quistica. |
| CN112876524B (zh) * | 2021-01-26 | 2022-10-28 | 上海法默生物科技有限公司 | 一种瑞德西韦中间体的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| WO2004100868A2 (en) * | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
| US7429596B2 (en) * | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
| BRPI0619146A2 (pt) * | 2005-12-02 | 2011-09-13 | Bayer Pharmaceuticals Corp | derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis |
| US7772231B2 (en) * | 2005-12-29 | 2010-08-10 | Abbott Laboratories | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors |
| KR20150038395A (ko) * | 2006-04-04 | 2015-04-08 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | 키나제 길항물질 |
| WO2009062118A2 (en) * | 2007-11-07 | 2009-05-14 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| BR112012019666A2 (pt) * | 2010-02-05 | 2017-06-20 | Bayer Ip Gmbh | estimuladores da sgc ou ativadores da sgc individualmente e em combinação com inibidores da pde5 para o tratamento de fibrose cística |
| UY34484A (es) * | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| ES2672018T3 (es) * | 2013-07-02 | 2018-06-12 | Rhizen Pharmaceuticals S.A. | Inhibidores de proteína cinasa PI3K, particularmente inhibidores delta y/o gamma |
| SG10202106949XA (en) * | 2016-11-18 | 2021-07-29 | Cystic Fibrosis Found | Pyrrolopyrimidines as cftr potentiators |
-
2017
- 2017-12-14 CN CN201780086700.9A patent/CN110300589B/zh active Active
- 2017-12-14 JP JP2019531417A patent/JP7150721B2/ja active Active
- 2017-12-14 AU AU2017378324A patent/AU2017378324B2/en active Active
- 2017-12-14 MX MX2019007135A patent/MX391651B/es unknown
- 2017-12-14 SG SG10201911076QA patent/SG10201911076QA/en unknown
- 2017-12-14 SG SG10201911221RA patent/SG10201911221RA/en unknown
- 2017-12-14 CA CA3046968A patent/CA3046968A1/en active Pending
- 2017-12-14 US US15/841,902 patent/US10131670B2/en active Active
- 2017-12-14 EP EP17879832.8A patent/EP3554506B1/en active Active
- 2017-12-14 WO PCT/US2017/066317 patent/WO2018112149A1/en not_active Ceased
- 2017-12-14 RU RU2019120990A patent/RU2753056C2/ru active
-
2018
- 2018-09-17 US US16/132,894 patent/US10208053B2/en active Active
- 2018-09-17 US US16/132,960 patent/US10377762B2/en active Active
-
2019
- 2019-07-09 US US16/506,883 patent/US10766904B2/en active Active
-
2021
- 2021-12-02 AU AU2021277702A patent/AU2021277702B2/en active Active